Highlights of weekly biotech stock moves

Biogen Idec Inc. (NASDAQ:BIIB) was up $8.39 to $235.24 last week after submitting a BLA to FDA for Plegridy peginterferon beta-1a (BIIB017) to treat relapsing forms of multiple sclerosis (MS). The company said it expects to submit an MAA to EMA in the coming weeks.

Celgene Corp. (NASDAQ:CELG) was off $2.33 to $122.58 last week after FDA accepted and granted Priority Review to an sNDA to expand the label of Abraxane nab-paclitaxel to include first-line treatment of advanced pancreatic cancer in combination with gemcitabine. The PDUFA date is Sept. 21...